CTLA4 and hepatocellular carcinoma: Although current treatment paradigms for advanced HCC increasingly emphasize immunotherapy—particularly immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 blockade [38,39]—our study did not investigate whether Haprolid exerts immunomodulatory effects.